Treatment Resistant Depression - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Treatment Resistant Depression - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Treatment Resistant Depression: Overview
The term “treatment resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment. Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.
'Treatment Resistant Depression - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Treatment Resistant Depression pipeline landscape is provided which includes the disease overview and Treatment Resistant Depression treatment guidelines. The assessment part of the report embraces, in depth Treatment Resistant Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Treatment Resistant Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Treatment Resistant Depression Emerging Drugs
Further product details are provided in the report……..
Treatment Resistant Depression: Therapeutic Assessment
This segment of the report provides insights about the different Treatment Resistant Depression drugs segregated based on following parameters that define the scope of the report, such as:
Treatment Resistant Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Treatment Resistant Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Treatment Resistant Depression drugs.
Treatment Resistant Depression Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Treatment Resistant Depression - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Treatment Resistant Depression: Overview
The term “treatment resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment. Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.
'Treatment Resistant Depression - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Treatment Resistant Depression pipeline landscape is provided which includes the disease overview and Treatment Resistant Depression treatment guidelines. The assessment part of the report embraces, in depth Treatment Resistant Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Treatment Resistant Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.
This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Treatment Resistant Depression Emerging Drugs
- Psilocybin: COMPASS Pathways
- AXS-05: Axsome Therapeutics
Further product details are provided in the report……..
Treatment Resistant Depression: Therapeutic Assessment
This segment of the report provides insights about the different Treatment Resistant Depression drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Treatment Resistant Depression
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Treatment Resistant Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Treatment Resistant Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Treatment Resistant Depression drugs.
Treatment Resistant Depression Report Insights
- Treatment Resistant Depression Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Treatment Resistant Depression drugs?
- How many Treatment Resistant Depression drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Treatment Resistant Depression?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Treatment Resistant Depression therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Treatment Resistant Depression and their status?
- What are the key designations that have been granted to the emerging drugs?
- Axsome Therapeutics
- COMPASS Pathways
- Merck Sharp & Dohme Corp.
- Navitor Pharmaceuticals, Inc.
- Taisho Pharmaceutical Co., Ltd.
- GH Research Limited
- Novartis Pharmaceuticals
- Reckitt Benckiser LLC
- Relmada Therapeutics, Inc.
- SAGE Therapeutics
- Navitor Pharmaceuticals
- Sumitomo Dainippon Pharma
- Alkermes
- AbbVie
- Janssen Pharmaceuticals
- Celon Pharma
- ACADIA Pharmaceuticals
- Pherin Pharmaceuticals
- ATAI Life Sciences
- Psilocybin
- AXS-05
- MK-1942
- NV-5138
- TS-161
- GH 001
- MIJ821
- venlafaxine XR
- REL-1017
- SAGE-217
- NV-5138
- SEP-378614
- ALKS-5461
- Cariprazine
- Seltorexant
- Esketamine DPI
- Pimavanserin
- PH 10 nasal spray
- Arketamine
Introduction
Executive Summary
Treatment Resistant Depression: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
AXS-05: Axsome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Psilocybin: COMPASS Pathways
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SEP-378614: Sumitomo Dainippon Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Treatment Resistant Depression Key Companies
Treatment Resistant Depression Key Products
Treatment Resistant Depression- Unmet Needs
Treatment Resistant Depression- Market Drivers and Barriers
Treatment Resistant Depression- Future Perspectives and Conclusion
Treatment Resistant Depression Analyst Views
Treatment Resistant Depression Key Companies
Appendix
Executive Summary
Treatment Resistant Depression: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
AXS-05: Axsome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Psilocybin: COMPASS Pathways
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SEP-378614: Sumitomo Dainippon Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Treatment Resistant Depression Key Companies
Treatment Resistant Depression Key Products
Treatment Resistant Depression- Unmet Needs
Treatment Resistant Depression- Market Drivers and Barriers
Treatment Resistant Depression- Future Perspectives and Conclusion
Treatment Resistant Depression Analyst Views
Treatment Resistant Depression Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Treatment Resistant Depression
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Treatment Resistant Depression
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Treatment Resistant Depression
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Treatment Resistant Depression
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
